查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1585673

生物相似藥單株抗體市場：按藥物類別、應用分類 - 2025-2030 年全球預測

Biosimilar Monoclonal Antibodies Market by Drug Class (Abciximab, Adalimumab, Bevacizumab), Application (Diagnostic, Protein Purification, Therapeutic) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年，單株抗體生物相似藥市值為76.9億美元，預計2024年將達到94.7億美元，複合年成長率為23.19%，2030年將達到331.4億美元。

生物相似藥單株抗體代表了治療生物技術的重要發展，被定義為實驗室製造的分子，旨在模仿原始生技藥品（尤其是單株抗體）的功效。這些生物相似藥在治療癌症、自體免疫疾病、感染疾病等方面提供了有效且通常更具成本效益的替代方案，在全球需求的推動下提供了負擔得起的醫療保健解決方案。對這些生物相似藥的需求在於它們有可能擴大患者獲得挽救生命的治療的機會，減少醫療保健支出，並維持財政負擔沉重的醫療保健系統。其應用涵蓋腫瘤學、血液學、免疫學和神經學，最終用於醫院、專科診所和研究機構。推動市場成長的因素包括原始生技藥品的專利到期、政府的支持性法規結構以及醫療保健專業人員和患者的日益接受。

主要市場統計
基準年[2023] 76.9億美元
預測年份 [2024] 94.7億美元
預測年份 [2030] 331.4億美元
複合年成長率（%） 23.19%

主要成長機會包括分析技術和製程最佳化的持續進步，以加強生物相似藥的開發，以及增加對生物技術新興企業和成熟製藥公司的投資，以利用利潤豐厚的生物相似藥領域。然而，限制因素包括高昂的研發成本、複雜的製造流程、嚴格的監管要求以及相關人員之間達成相容性協議的挑戰。為了克服這些障礙，改進製造流程、生物相似藥抗體偶聯物和個人化療法等領域的技術創新有望實現。公司應專注於臨床試驗和市場進入的策略夥伴關係和聯盟。此外，具有競爭性製造優勢的區域市場（例如亞太地區）也提供了擴張的機會。徹底的市場分析表明，生物相似藥單株抗體市場是一個具有成長潛力的強勁市場，但其成功將取決於創新者駕馭監管環境、提高產品質量，以及醫療保健提供者能否有效證明成本效益。這項見解凸顯了市場的動態本質及其持續演變和創新主導成長的準備。

市場動態：揭示快速發展的生物相似藥單株抗體市場的關鍵市場洞察

供需的動態交互作用正在改變生物相似藥單株抗體市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 擴展具有成本效益的生物相似藥單株抗體
    • 老年人口增加，癌症和其他慢性病發生率上升
    • 各國醫療保健支出增加
  • 市場限制因素
    • 缺乏預分析測試的政府法規
  • 市場機會
    • 增加無機策略以擴大生產設施
    • 專注研發推出創新產品平臺
  • 市場挑戰
    • 製造流程複雜

波特五力：駕馭生物相似藥單株抗體市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解生物相似藥單株抗體市場的外部影響

外部宏觀環境因素在塑造生物相似藥單株抗體市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解生物相似藥單株抗體市場的競爭格局

對生物相似藥單株抗體市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣生物類似單株抗體市場供應商的績效評估

FPNV定位矩陣是評估生物相似藥單株抗體市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了生物相似藥單株抗體市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對生物相似藥單株抗體市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 增加具有成本效益的生物相似藥單株抗體的採用
      • 老年人口不斷增加，癌症和其他慢性病發生率上升
      • 經濟體中的醫療成本增加
    • 抑制因素
      • 缺乏預分析測試的政府法規
    • 機會
      • 增加無機策略以擴大生產設施
      • 專注研發推出創新產品平臺
    • 任務
      • 與製造過程相關的複雜性
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依藥物類別分類的生物相似藥單株抗體市場

  • 阿昔單抗
  • Adalimumab
  • Bevacizumab
  • Infliximab
  • Rituximab
  • 曲妥珠單抗

第7章 生物相似藥單株抗體市場：依應用分類

  • 診斷
    • MAB在生化分析的應用
      • 癌症
      • 荷爾蒙失調
      • 感染疾病
      • 懷孕
    • MAB 在診斷影像的應用
      • 動脈硬化
      • 細菌感染疾病
      • 癌症
      • 心血管疾病
      • 深層靜脈栓塞症
  • 蛋白質精製
  • 治療性的
    • MAB 作為直接治療劑
    • MAB 作為治療中的標靶藥物

第8章美洲生物相似藥單株抗體市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區生物類似單株抗體市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章 歐洲、中東和非洲生物類似單株抗體市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • 3SBio Inc.
  • AbbVie, Inc.
  • Amgen Inc.
  • Biocon Limited
  • BioXpress Therapeutics SA
  • CH Boehringer Sohn AG & Co. KG
  • Celltrion Healthcare Co Ltd.
  • Coherus BioSciences, Inc.
  • Dr. Reddy's Laboratories Ltd
  • Genor BioPharma Co. Ltd
  • Hisun Pharmaceutical
  • Intas Pharmaceuticals Limited
  • Novartis AG
  • Pfizer, Inc.
  • Reliance Life Sciences
  • Samsung Biologics
Product Code: MRR-437D45957E9F

The Biosimilar Monoclonal Antibodies Market was valued at USD 7.69 billion in 2023, expected to reach USD 9.47 billion in 2024, and is projected to grow at a CAGR of 23.19%, to USD 33.14 billion by 2030.

Biosimilar monoclonal antibodies represent a crucial evolution in therapeutic biotechnology, defined as lab-crafted molecules designed to mimic the efficacy of original biologics, specifically monoclonal antibodies. These biosimilars offer an effective, often more cost-efficient alternative in treating conditions like cancer, autoimmune disorders, and infectious diseases, driven by the global demand for affordable healthcare solutions. The necessity of these biosimilars lies in their potential to broaden patient access to life-saving treatments, reduce healthcare expenditure, and sustain healthcare systems under financial strain. Their application spans oncology, hematology, immunology, and neurology, with targeted end-use among hospitals, specialty clinics, and research institutes. The market's ascent is fueled by factors such as the expiration of patents for original biologics, supportive governmental regulatory frameworks, and increasing acceptance from healthcare practitioners and patients.

KEY MARKET STATISTICS
Base Year [2023] USD 7.69 billion
Estimated Year [2024] USD 9.47 billion
Forecast Year [2030] USD 33.14 billion
CAGR (%) 23.19%

Key growth opportunities include ongoing advancements in analytical technologies and process optimizations that enhance biosimilar development, along with growing investments in biotech startups and established pharmaceutical firms capitalizing on the lucrative biosimilar space. Meanwhile, the market faces limitations such as high R&D costs, complexities in manufacturing processes, stringent regulatory requirements, and challenges in achieving interchangeability consensus among stakeholders. To overcome these barriers, innovation in areas such as improved production processes, biosimilar antibody conjugates, and personalized therapies are promising. Businesses should focus on strategic partnerships and collaborations for clinical trials and market access. Furthermore, regional markets offering competitive manufacturing advantages, such as Asia-Pacific, present opportunities for expansion. Thorough market analysis indicates that while the biosimilar monoclonal antibody market is robust with growth potential, success hinges on innovators' ability to navigate regulatory landscapes, enhance product quality, and effectively demonstrate cost-benefit to healthcare providers. This insight underscores the dynamic nature of the market, highlighting its readiness for continued evolution and innovation-driven growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Biosimilar Monoclonal Antibodies Market

The Biosimilar Monoclonal Antibodies Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of cost-efficient biosimilar monoclonal antibodies
    • Growth in geriatric population and rising incidence of cancer and other chronic diseases
    • Increasing healthcare expenditure in economies
  • Market Restraints
    • Government regulations towards the absence of pre-analytical tests
  • Market Opportunities
    • Rising number of inorganic strategies for the expansion of production facility
    • Focus on R&D to introduce innovative product pipeline
  • Market Challenges
    • Complexities associated with manufacturing processes

Porter's Five Forces: A Strategic Tool for Navigating the Biosimilar Monoclonal Antibodies Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Biosimilar Monoclonal Antibodies Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Biosimilar Monoclonal Antibodies Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Biosimilar Monoclonal Antibodies Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Biosimilar Monoclonal Antibodies Market

A detailed market share analysis in the Biosimilar Monoclonal Antibodies Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Biosimilar Monoclonal Antibodies Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Biosimilar Monoclonal Antibodies Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Biosimilar Monoclonal Antibodies Market

A strategic analysis of the Biosimilar Monoclonal Antibodies Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Biosimilar Monoclonal Antibodies Market, highlighting leading vendors and their innovative profiles. These include 3SBio Inc., AbbVie, Inc., Amgen Inc., Biocon Limited, BioXpress Therapeutics SA, C.H. Boehringer Sohn AG & Co. KG, Celltrion Healthcare Co Ltd., Coherus BioSciences, Inc., Dr. Reddy's Laboratories Ltd, Genor BioPharma Co. Ltd, Hisun Pharmaceutical, Intas Pharmaceuticals Limited, Novartis AG, Pfizer, Inc., Reliance Life Sciences, and Samsung Biologics.

Market Segmentation & Coverage

This research report categorizes the Biosimilar Monoclonal Antibodies Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Abciximab, Adalimumab, Bevacizumab, Infliximab, Rituximab, and Trastuzumab.
  • Based on Application, market is studied across Diagnostic, Protein Purification, and Therapeutic. The Diagnostic is further studied across MABs in Biochemical Analysis and MABs in Diagnostic Imaging. The MABs in Biochemical Analysis is further studied across Cancers, Hormonal Disorders, Infectious Diseases, and Pregnancy. The MABs in Diagnostic Imaging is further studied across Atherosclerosis, Bacterial Infections, Cancers, Cardiovascular Diseases, and Deep Vein Thrombosis. The Therapeutic is further studied across MABs as Direct Therapeutic Agents and MABs as Targeting Agents in Therapy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of cost-efficient biosimilar monoclonal antibodies
      • 5.1.1.2. Growth in geriatric population and rising incidence of cancer and other chronic diseases
      • 5.1.1.3. Increasing healthcare expenditure in economies
    • 5.1.2. Restraints
      • 5.1.2.1. Government regulations towards the absence of pre-analytical tests
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising number of inorganic strategies for the expansion of production facility
      • 5.1.3.2. Focus on R&D to introduce innovative product pipeline
    • 5.1.4. Challenges
      • 5.1.4.1. Complexities associated with manufacturing processes
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Biosimilar Monoclonal Antibodies Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Abciximab
  • 6.3. Adalimumab
  • 6.4. Bevacizumab
  • 6.5. Infliximab
  • 6.6. Rituximab
  • 6.7. Trastuzumab

7. Biosimilar Monoclonal Antibodies Market, by Application

  • 7.1. Introduction
  • 7.2. Diagnostic
    • 7.2.1. MABs in Biochemical Analysis
      • 7.2.1.1. Cancers
      • 7.2.1.2. Hormonal Disorders
      • 7.2.1.3. Infectious Diseases
      • 7.2.1.4. Pregnancy
    • 7.2.2. MABs in Diagnostic Imaging
      • 7.2.2.1. Atherosclerosis
      • 7.2.2.2. Bacterial Infections
      • 7.2.2.3. Cancers
      • 7.2.2.4. Cardiovascular Diseases
      • 7.2.2.5. Deep Vein Thrombosis
  • 7.3. Protein Purification
  • 7.4. Therapeutic
    • 7.4.1. MABs as Direct Therapeutic Agents
    • 7.4.2. MABs as Targeting Agents in Therapy

8. Americas Biosimilar Monoclonal Antibodies Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Biosimilar Monoclonal Antibodies Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Biosimilar Monoclonal Antibodies Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. 3SBio Inc.
  • 2. AbbVie, Inc.
  • 3. Amgen Inc.
  • 4. Biocon Limited
  • 5. BioXpress Therapeutics SA
  • 6. C.H. Boehringer Sohn AG & Co. KG
  • 7. Celltrion Healthcare Co Ltd.
  • 8. Coherus BioSciences, Inc.
  • 9. Dr. Reddy's Laboratories Ltd
  • 10. Genor BioPharma Co. Ltd
  • 11. Hisun Pharmaceutical
  • 12. Intas Pharmaceuticals Limited
  • 13. Novartis AG
  • 14. Pfizer, Inc.
  • 15. Reliance Life Sciences
  • 16. Samsung Biologics

LIST OF FIGURES

  • FIGURE 1. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET RESEARCH PROCESS
  • FIGURE 2. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET DYNAMICS
  • TABLE 7. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ABCIXIMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ADALIMUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLIXIMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RITUXIMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TRASTUZUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HORMONAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PREGNANCY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ATHEROSCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PROTEIN PURIFICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS AS DIRECT THERAPEUTIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS AS TARGETING AGENTS IN THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 64. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 65. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 72. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 80. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 84. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 85. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 86. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 87. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 89. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 90. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 91. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 92. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 95. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 96. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 97. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 98. INDONESIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 99. INDONESIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. INDONESIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 101. INDONESIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 102. INDONESIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 103. INDONESIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 104. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 105. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 107. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 108. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 109. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 110. MALAYSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 111. MALAYSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. MALAYSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 113. MALAYSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 114. MALAYSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 115. MALAYSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 116. PHILIPPINES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. PHILIPPINES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 120. PHILIPPINES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 121. PHILIPPINES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 122. SINGAPORE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 123. SINGAPORE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. SINGAPORE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 125. SINGAPORE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 126. SINGAPORE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 127. SINGAPORE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 133. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 134. TAIWAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 135. TAIWAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. TAIWAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 137. TAIWAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 138. TAIWAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 139. TAIWAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 140. THAILAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 141. THAILAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. THAILAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 143. THAILAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 144. THAILAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 145. THAILAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 146. VIETNAM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 147. VIETNAM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. VIETNAM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 149. VIETNAM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 150. VIETNAM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 151. VIETNAM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 159. DENMARK BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 160. DENMARK BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 161. DENMARK BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 162. DENMARK BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 163. DENMARK BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 164. DENMARK BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 165. EGYPT BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 166. EGYPT BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 167. EGYPT BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 168. EGYPT BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 169. EGYPT BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 170. EGYPT BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 171. FINLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 172. FINLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. FINLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 174. FINLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 175. FINLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 176. FINLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 177. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 178. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 179. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 180. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 181. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 182. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 183. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 184. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 186. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 187. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 188. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 189. ISRAEL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 190. ISRAEL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 191. ISRAEL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 192. ISRAEL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 193. ISRAEL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 194. ISRAEL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 195. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 196. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 197. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 198. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 199. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 200. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 202. NETHERLANDS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 204. NETHERLANDS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 206. NETHERLANDS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 207. NIGERIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 208. NIGERIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 209. NIGERIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 210. NIGERIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 211. NIGERIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 212. NIGERIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 213. NORWAY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 214. NORWAY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 215. NORWAY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 216. NORWAY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 217. NORWAY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 218. NORWAY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 219. POLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 220. POLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 221. POLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 222. POLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 223. POLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 224. POLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 225. QATAR BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 226. QATAR BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 227. QATAR BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 228. QATAR BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 229. QATAR BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 230. QATAR BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 231. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 232. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 233. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 234. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 235. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 236. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 238. SAUDI ARABIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 240. SAUDI ARABIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 242. SAUDI ARABIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 248. SOUTH AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 249. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 250. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 251. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 252. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 253. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 254. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 255. SWEDEN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 256. SWEDEN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 257. SWEDEN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 258. SWEDEN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 259. SWEDEN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 260. SWEDEN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 262. SWITZERLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 264. SWITZERLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 266. SWITZERLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 267. TURKEY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 268. TURKEY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 269. TURKEY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 270. TURKEY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 271. TURKEY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 272. TURKEY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED ARAB EMIRATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED ARAB EMIRATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
  • TABLE 282. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
  • TABLE 284. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 285. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 286. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET, FPNV POSITIONING MATRIX, 2023